Logo

Evotec to Screen Compounds for Genentech

May 10, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec said today that it will screen small molecule compounds for drug developer Genentech under a new collaborative agreement.

Under the multi-year alliance, Evotec will use its disease knowledgebase and drug discovery platform to test small molecule candidates for the Roche subsidiary. The research will include assay development, high-throughput screening, structural biology, and medicinal chemistry services, Hamburg-based Evotec said.

Financial terms of the agreement were not released.

Filed under

Genentech
Evotec
high-throughput screening
drug screening
Roche
Breaking News
The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.